Home > Healthcare > Pharmaceuticals > Finished Drug Form > Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Market Trends

Report ID: GMI12537
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Erectile Dysfunction Drugs Market Trends

Aging is a significant risk factor for erectile dysfunction, positioning the growing global elderly population as a key catalyst of the ED drugs market.
The United Nations ESCAP anticipates that the elderly population in Asia-Pacific will more than double, from 630 million in 2020 to roughly 1.3 billion by 2050. Thus, as more regions see increasing numbers of individuals over age 50, the prevalence of ED is expected to grow, driving consistent demand for effective treatment options.
Therefore, this demographic shift not only boosts demand but also underscores the need for safe, long-lasting, and user-friendly ED treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The erectile dysfunction drugs industry was valued at approximately USD 2.9 billion in 2024 and is estimated to grow at a 9.2% CAGR from 2025 to 2034, driven by increasing awareness and acceptance of ED treatments.

The Viagra (Sildenafil Citrate) segment held the largest revenue size of USD 1.5 billion in 2024 and is expected to witness significant growth due to its established brand recognition and proven efficacy.

The U.S. erectile dysfunction drugs market is projected to grow significantly, reaching USD 2.6 billion by 2034, fueled by the rapid expansion of telemedicine services.

Key players in the market include Bayer, Eli Lilly and Company, Endo, Futura Medical, Hims & Hers Health, Lupin, Meda Pharmaceuticals, Petros Pharmaceuticals, Pfizer, Sandoz, Simple Pharma, Sun Pharmaceutical Industries, and Teva Pharmaceutical Industries.